The current BsAbs produced by this molecular platform are JNJ-63709178 (phase I: NCT02715011), which targets CD3 and CD123 for AML and JNJ-61186372 (phase I: NCT02609776), which targets EGFR and c-MET for NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.